Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Randolph P. Matthews"'
Autor:
Randolph P. Matthews, Wendy Ankrom, Evan Friedman, Deanne Jackson Rudd, Yang Liu, Robin Mogg, Deborah Panebianco, Inge De Lepeleire, Magdalena Petkova, Jay A. Grobler, Selwyn Aubrey Stoch, Marian Iwamoto
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 5, Pp 1935-1944 (2021)
Abstract Islatravir (MK‐8591) is a nucleoside analogue in development for the treatment and prevention of HIV‐1. Two phase 1 trials were conducted during initial evaluation of islatravir: rising single doses (Study 1) and rising multiple doses (S
Externí odkaz:
https://doaj.org/article/6f26b820a53d4b0c9215bb7d0664b680
Autor:
Inge De Lepeleire, Randolph P. Matthews, Dirk Schürmann, Deanne J. Rudd, Vanessa Levine, Sabrina Fox-Bosetti, Sandra Zhang, Martine Robberechts, Andreas Hüser, DariaJ Hazuda, JayA Grobler, Aubrey Stoch, Marian Iwamoto
Publikováno v:
Journal of Virus Eradication, Vol 3, Iss , Pp 2- (2017)
Externí odkaz:
https://doaj.org/article/6c4df87c6b224d3eaa78329f23363c77
Autor:
Randolph P. Matthews, Youfang Cao, Munjal Patel, Vanessa L. Weissler, Arinjita Bhattacharyya, Inge De Lepeleire, Stefanie Last, Juan C. Rondon, Ryan Vargo, S. Aubrey Stoch, Marian Iwamoto
Publikováno v:
Antimicrobial Agents and Chemotherapy. 66
Islatravir (MK-8591) is a high-potency reverse transcriptase translocation inhibitor in development for the treatment of HIV-1 infection. Data from preclinical and clinical studies suggest that ~30% to 60% of islatravir is excreted renally and that i
Autor:
Randolph P. Matthews, Xiaowei Zang, Stephanie E. Barrett, Athanas Koynov, Adrian Goodey, Tycho Heimbach, Vanessa L. Weissler, Carlien Leyssens, Tom Reynders, Zhiqing Xu, Sylvie Rottey, Ryan Vargo, Michael N. Robertson, S. Aubrey Stoch, Marian Iwamoto
Publikováno v:
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
Background:Islatravir (MK-8591) is a deoxyadenosine analog in development for the treatment and prevention of HIV-1 infection. An islatravir-eluting implant could provide an additional option for pre-exposure prophylaxis (PrEP).Setting:Previous data
Autor:
Danielle Armas, Sabrina Fox-Bosetti, Saijuan Zhang, Deanne Jackson Rudd, Evan J. Friedman, Randolph P. Matthews, Kerry L. Fillgrove, S. Aubrey Stoch, Marian Iwamoto
Publikováno v:
Clinical Pharmacology in Drug Development. 10:1432-1441
Islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, is in clinical development for the treatment and prevention of HIV-1 infection. Because islatravir may be coadministered with other antiretroviral agents, assess
Autor:
Tom Reynders, Sylvie Rottey, Jay A. Grobler, Adrian Goodey, Liesbeth Haspeslagh, Stephanie E. Barrett, S. Aubrey Stoch, Ryan C. Vargo, Saijuan Zhang, Munjal Patel, Randolph P. Matthews, Marian Iwamoto
Publikováno v:
Nature Medicine. 27:1712-1717
Islatravir (MK-8591) is a highly potent type 1 human immunodeficiency virus (HIV-1) nucleoside reverse transcriptase translocation inhibitor with a long intracellular half-life that is in development for the prevention and treatment of HIV-1. We cond
Autor:
Kerry L. Fillgrove, Charles Tomek, Saijuan Zhang, S. Aubrey Stoch, Randolph P. Matthews, Marian Iwamoto, Deanne Jackson Rudd
Publikováno v:
Clinical Drug Investigation
Background and Objectives Islatravir (MK-8591) is a novel nucleoside analogue in development for the treatment and prevention of HIV-1 infection. Doravirine is a non-nucleoside reverse transcriptase inhibitor indicated for the treatment of HIV-1 infe
Autor:
Deanne Jackson Rudd, Jay A. Grobler, Marian Iwamoto, Ryan C. Vargo, Randolph P. Matthews, Laura M. Sterling, S. Aubrey Stoch, Kerry L. Fillgrove, Saijuan Zhang
Publikováno v:
JAIDS Journal of Acquired Immune Deficiency Syndromes. 88:314-321
BACKGROUND Islatravir (MK-8591) is a novel nucleoside analog in development for the treatment and prevention of HIV-1 infection. Islatravir has potent antiviral activity and a long intracellular half-life. SETTING A 3-panel, randomized, double-blind,
Autor:
Randolph P. Matthews, Rebecca E Wrishko, Mary Beth Dorr, Diana Montgomery, Lori M. Tobias, Ka Lai Yee
Publikováno v:
Clinical Pharmacology in Drug Development. 9:330-340
Bezlotoxumab is a fully human monoclonal antibody that binds and neutralizes Clostridium difficile toxin B. This analysis investigated the potential of bezlotoxumab to induce immunogenicity in healthy phase 1 trial participants and in phase 2/3 trial
Autor:
Wendy Ankrom, Deanne Jackson Rudd, Saijuan Zhang, Kerry L. Fillgrove, Kezia N. Gravesande, Randolph P. Matthews, Darin Brimhall, S. Aubrey Stoch, Marian N. Iwamoto
Publikováno v:
Journal of the International AIDS Society
Introduction Hormonal contraceptives are among the most effective forms of reversible contraception, but many other compounds, including some antiretrovirals, have clinically meaningful drug–drug interactions (DDIs) with hormonal contraceptives. Is